Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin and psychosis.

J W Sander1, Y M Hart, M R Trimble

  • 1INSEG-Institute of Neurology, National Hospital for Neurology, London.

Journal of Neurology, Neurosurgery, and Psychiatry
|May 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

African leadership in brain diplomacy: The Yaoundé declaration advances the global brain economy playbook for better brain health.

Neuroscience·2025
Same author

High prevalence of epilepsy in Southern and Northern Rwanda: Myth or reality?

Tropical medicine & international health : TM & IH·2024
Same author

Personalised music as a treatment for epilepsy.

Epilepsy & behavior : E&B·2024
Same author

Late-life terminal seizure freedom in drug-resistant epilepsy: "Burned-out epilepsy".

Journal of the neurological sciences·2021
Same author

The impact of COVID-19 on epilepsy care: Perspectives from UK healthcare workers.

Epilepsy & behavior reports·2021
Same author

Comparing two classification schemes for seizures and epilepsy in rural China.

European journal of neurology·2018

Vigabatrin, an antiepileptic drug, can cause psychosis in patients with severe epilepsy, even those without prior history. Careful monitoring and cautious initiation are recommended, especially for patients with a history of psychosis.

Area of Science:

  • Neurology
  • Psychiatry
  • Pharmacology

Background:

  • Severe epilepsy often requires potent antiepileptic drugs.
  • Vigabatrin is a novel antiepileptic medication.
  • Psychiatric side effects of antiepileptics require careful consideration.

Purpose of the Study:

  • To report cases of psychosis associated with vigabatrin use in epilepsy patients.
  • To analyze the relationship between vigabatrin dosage, seizure patterns, and psychosis onset.
  • To highlight the need for monitoring vigabatrin-induced behavioral changes.

Main Methods:

  • Case series reporting 14 patients with epilepsy and subsequent psychosis after vigabatrin prescription.
  • Analysis of patient history, seizure activity, vigabatrin dosage, and timing of psychosis.

Related Experiment Videos

  • Inclusion/exclusion criteria defined for the case series.

    • Main Results:

    • 14 cases of psychosis observed in patients treated with vigabatrin for severe epilepsy.
    • Nine patients had no prior history of psychosis.
    • Psychosis onset varied from 5 days to 32 weeks after vigabatrin initiation, with a mean dose of 2580 mg.

    Conclusions:

    • Vigabatrin can induce psychosis in epilepsy patients, sometimes without a prior psychiatric history.
    • The onset of psychosis may correlate with seizure pattern changes or drug dosage.
    • Vigabatrin should be initiated cautiously in severe epilepsy patients, with particular attention to those with a history of psychosis.